UniCredit Bonus Zert PFE 28.06.20.../ DE000HD3TX92 /
2024-05-02 9:55:09 AM | Chg.+12.250 | Bid9:58:11 AM | Ask9:58:11 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
42.620EUR | +40.34% | 42.520 Bid Size: 500 |
42.670 Ask Size: 500 |
Pfizer Inc | - USD | 2024-06-28 | Call |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03-22
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
03-07
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
03-05
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire
02-28
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
02-27
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...
GlobeNewswire
02-16
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Befo...
GlobeNewswire
02-08
ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Importan...
GlobeNewswire
02-06
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment o...
GlobeNewswire
01-26
ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadl...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
2023-12-13
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associ...
GlobeNewswire
2023-12-05
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Pa...
GlobeNewswire
2023-12-04
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire
2023-12-04
Truveta welcomes Patrick Caubel, Pfizer Chief Safety Officer, to its Board of Directors